For decades, geneticists have relied on the classical genetic code to interpret how DNA sequences translate into proteins. However, a profound mystery persisted: the regulatory framework governing gene expression plasticity remained elusive. While regulatory elements like promoters are known to modulate gene activity, the complex ‘grammar’—or regulatory syntax—that orchestrates precise gene toggling had not been deciphered. This regulatory system is responsible for spatiotemporal gene expression, determining cell identity, behavior, and response to environmental cues.

The urgency of decoding this genomic control system cannot be overstated, especially given that many cancer-related mutations reside in non-coding regions traditionally deemed as “junk DNA.” These mutations often disrupt gene regulation and contribute to tumor development and progression. Historically, interpreting the pathogenic potential of such mutations was a major bottleneck in cancer research. PARM directly addresses this challenge by providing a sophisticated computational tool that can interpret regulatory DNA sequences and predict their effects on gene activity with exceptional accuracy.

The development of PARM was made possible through a collaborative initiative, the PERICODE project, which united seven research groups under the Oncode Institute. Utilizing cutting-edge experimental techniques pioneered in the Bas van Steensel laboratory at the Netherlands Cancer Institute (NKI), researchers employed massively parallel reporter assays (MPRA) to generate millions of quantitative measurements. These experiments systematically tested how myriad short DNA sequences influenced gene expression levels in specific cell types, thereby creating an unprecedented data repository linking promoter architecture to functional output.

Yet, possessing vast data alone is insufficient for biological insight. Here, Jeroen de Ridder’s group at UMC Utrecht harnessed advanced artificial intelligence algorithms to model these experimental results. Unlike conventional AI models that rely on imperfect proxy data, PARM benefited from precisely engineered, high-fidelity datasets explicitly crafted for deciphering gene regulation. This intentional synergy between experimental design and machine learning empowered the creation of an ultra-efficient model fine-tuned for specific cellular environments. By training on meticulously controlled datasets, PARM captures nuanced, cell-type specific regulatory logics that previous models missed.

Demonstrating extraordinary predictive power, PARM elucidates how gene regulation varies not only between cell types but also dynamically changes under environmental stimuli, such as exposure to drugs or hormones. This dynamic modeling revealed the detailed architecture of regulatory elements—effectively exposing each gene’s “on” and “off” control switches and their combinatorial interactions. Importantly, the scientific team subjected every prediction to rigorous experimental validation, assuring the robustness and biological fidelity of the model’s insights.

PARM also innovates through its remarkable computational efficiency. Previous state-of-the-art models, like Google DeepMind’s AlphaGenome, while powerful, demanded colossal computational resources making them less accessible to many research laboratories worldwide. PARM’s architecture requires approximately one thousand times less computing power, making it achievable for typical academic environments. This efficiency was achieved without sacrificing performance, meaning researchers worldwide can now simulate complex regulatory landscapes using modest laboratory setups and conventional computing hardware within a single day.

This breakthrough has profound implications for cancer biology and therapeutic development. By enabling accurate prediction of regulatory mutation impacts in specific cell types and conditions, PARM opens novel avenues for precision oncology, such as designing patient-specific diagnostics and stratified treatments. The ability to forecast how tumor cells may adapt or resist therapeutics at the level of gene regulation provides an invaluable resource for drug discovery and personalized medicine.

The success of PARM underscores the power of multidisciplinary collaboration bridging genomics, computational biology, and experimental biophysics. Funded by notable institutions such as the Oncode Institute and the AVL Foundation, this collective effort amalgamated expertise from Bas van Steensel’s group at NKI, Jeroen de Ridder’s team at UMC Utrecht, and several other leading genomic research labs. Such integration of experimental high-throughput approaches with deep learning signifies a paradigm shift in decoding biological complexity.

Importantly, PARM’s design also bridges the gap between scalability and interpretability, two features often mutually exclusive in AI. By tailoring its predictive models to highly specific cellular states, PARM manages to retain mechanistic interpretability—insight into the regulatory grammar—while scaling analyses across millions of variants. This combination promises to accelerate functional genomics research across a broad spectrum of diseases and biological systems beyond oncology.

Looking forward, the research community anticipates PARM’s versatility to expand substantially. Researchers can now systematically map gene regulatory changes across diverse human tissues, developmental stages, and disease contexts. The model’s adaptability to incorporate different stimulus-response patterns also sets the stage for unraveling how environmental factors and pharmacological agents reshape epigenetic landscapes, further enriching our understanding of gene control in health and disease.

As the frontiers of genomics advance deeper into the realm of regulatory DNA, tools like PARM will be indispensable for translating vast sequence data into actionable biological knowledge. This model not only demystifies how non-coding DNA dictates cellular phenotypes but also empowers a new generation of genomic medicine that integrates predictive, customizable insights into clinical workflows.

In sum, the advent of PARM signifies a scientific milestone: the ability to ‘read’ the language of gene regulation at unparalleled resolution and scale. By transforming gene regulatory decoding from an enigmatic black box into an interpretable and computable framework, PARM promises to accelerate breakthroughs in cancer biology, therapeutic design, and fundamental genomics, heralding a new era of precision in biomedical science.

Subject of Research: Cells

Article Title: Regulatory grammar in human promoters uncovered by MPRA-based deep learning

News Publication Date: 3-Feb-2026

Web References:

• Nature article
• PARM model portal

References:
Bas van Steensel, Jeroen de Ridder, et al. Regulatory grammar in human promoters uncovered by MPRA-based deep learning. Nature, 2026. DOI: 10.1038/s41586-025-10093-z

Image Credits: ©Netherlands Cancer Institute / Sanne Hijlkema

Keywords: Gene expression, Machine learning

Although individually rare, genetic disorders collectively affect an estimated 300 million people worldwide. These diseases stem from mutations in an overwhelming diversity of over 5,000 genes, leading to more than 7,000 clinical conditions. Current diagnostic protocols remain inadequate, with approximately 50% of suspected rare disease cases left undiagnosed due to the slow, disease-specific nature of testing. Patients and families frequently endure prolonged periods of uncertainty punctuated by invasive procedures, compounding emotional and economic distress.

Challenging the status quo, Dr. Daniella Hock and her team at the University of Melbourne have developed a minimally invasive proteomic test that leverages blood samples to survey thousands of proteins simultaneously. Unlike conventional genetic testing focused exclusively on DNA sequencing, this innovative method scrutinizes proteins—the active biological effectors synthesized by genes—thus providing a direct window into cellular function and dysfunction. By examining how genetic variants disrupt the structure or abundance of these proteins, the test sheds light on the pathological processes underlying rare diseases.

This proteome-centric approach holds several intrinsic advantages. Primarily, it offers an untargeted, comprehensive assay capable of detecting functional anomalies across a broad spectrum of genetic disorders, including those yet to be characterized. The technique’s ability to survey over 8,000 proteins within blood mononuclear cells corresponds to coverage of more than half of known Mendelian and mitochondrial disease-associated genes. This expansive coverage renders it an indispensable tool for holistic diagnosis rather than a series of piecemeal investigations.

Operational efficiency is another hallmark of this test. Requiring only one milliliter of blood from an infant—a negligible volume compared to traditional protocols—the testing process yields results in under three days, an essential consideration in acute care settings. Speed in diagnosis enables earlier therapeutic intervention, enhances patient outcomes, and opens pathways for informed clinical decision-making. This is particularly crucial for disorders where treatment windows are narrow and delays can severely hamper prognoses.

The methodology also uniquely incorporates familial trio analysis, whereby blood samples from the patient and both parents are concurrently evaluated. This triadic approach significantly improves the discrimination between affected individuals and carriers of recessive mutations. Carriers, possessing only one mutated allele, remain asymptomatic, whereas the patient inherits two defective copies. By clarifying inheritance patterns with higher confidence, trio analysis alleviates diagnostic ambiguity and informs reproductive counseling for families.

From a clinical perspective, the rapid and accurate molecular diagnosis precipitated by this new test obviates the need for prolonged, invasive diagnostic odysseys. Patients gain timely access to targeted therapies when available, improved prognostic clarity, and psychological relief through definitive answers. For families, these insights translate into expanded reproductive options, including prenatal and preimplantation genetic testing to mitigate recurrence risks in future pregnancies.

Economic considerations also weigh heavily in favor of the proteomic test. Preliminary studies in collaboration with the Melbourne School of Population and Global Health underscore that the cost of this comprehensive assay is comparable to existing genetic tests targeting specific conditions like mitochondrial diseases. However, its broader diagnostic scope inherently reduces cumulative healthcare expenditure by consolidating multiple test requisites into a single, efficient platform and by enabling prompt, appropriate medical management.

The scientific and medical community’s reception of this innovation is overwhelmingly optimistic. Dr. Hock emphasizes how the combination of minimal sample volume, rapid turnaround, and the precision of trio analysis has surpassed expectations in clinical applicability. Adoption of such proteomic techniques promises to reshape diagnostic algorithms in hospitals and clinical laboratories worldwide, ultimately transforming patient care paradigms.

Leading figures at the conference echoed these sentiments, advocating for non-invasive, agnostic approaches to diagnosis, including genome sequencing and comprehensive protein analysis. These technologies herald a future wherein previously intractable diagnostic enigmas are unraveled swiftly, providing families long-awaited answers and hope. The synergy between genomics and proteomics represents a formidable frontier in personalized medicine.

Technically, the proteomic analysis focuses on peripheral blood mononuclear cells (PBMCs), a rich reservoir of immune cells critical to understanding systemic and cellular manifestations of genetic diseases. The test quantifies relative protein expression levels, post-translational modifications, and interaction networks, enabling functional inference about variant pathogenicity that purely sequence-based diagnostics often miss. This integrative multi-omic perspective enhances biological insight and clinical relevance.

The implications for research are equally profound. By illuminating the functional consequences of genetic variants, many of which remain classified as variants of uncertain significance (VUS), this proteomic platform can expedite the discovery and validation of novel disease genes. This knowledge gap closure accelerates the translation of genomic data into actionable clinical intelligence, advancing the field of rare disease genomics.

In summary, this novel proteomic test spearheaded by Dr. Daniella Hock’s team signifies a pivotal advancement in rare disease diagnosis for infants and children. It offers a rapid, cost-effective, and broadly applicable tool that circumvents the limitations of targeted genetic testing. As this technology integrates into routine clinical practice, it promises to significantly reduce diagnostic odysseys, empower families with reproductive choices, and alleviate the burden on healthcare systems globally.

As the medical community continues to embrace such innovative modalities, the hope for timely and definitive diagnoses of rare diseases moves from ideal to inevitable. This shift stands to transform the lives of millions affected by these often devastating conditions and ushers in an era where precision medicine is accessible from the earliest moments of life.

Subject of Research: People

Article Title: Trio PBMC proteomics for rapid variant functionalisation in the diagnosis of rare diseases

News Publication Date: (Information not provided)

Web References: (Information not provided)

References: (Information not provided)

Image Credits: (Information not provided)

Keywords: Diseases and disorders, Health and medicine